Today, SHINGRIX is available and GSK can meet demand across all distribution channels. From the launch of SHINGRIX in 2017 through March 2020, demand for shingles immunization has been very strong. Over that time, we estimate approximately 17 million people in the US received at least one dose of SHINGRIX.1
However, national stay-at-home measures, prompted by the COVID-19 pandemic, have resulted in a significant decrease in patients seeking routine healthcare, including immunizations. This reduction in demand for vaccination has resulted in improved inventory of SHINGRIX.
In order to support and encourage a return to the robust pace and progress of immunization before the pandemic and timely second-dose completion, we have taken the following steps:
- Removed ordering caps
- Introduced direct-to-patient education via mass media (eg, television and digital)
You are encouraged to order through your preferred channel to help meet your needs for SHINGRIX. This includes ordering through your preferred wholesaler or via easy, online ordering at